Arthritis clinical trials are actively recruiting participants across the United States right now, with compensation typically ranging from $200 to $1,500 or more depending on the study type, duration, and number of visits required. Some rheumatoid arthritis trials advertise payments up to $1,900, while psoriatic arthritis studies have offered as much as $2,000. These aren’t vague promises — Clinical Research of West Florida, for example, is currently running RA studies involving up to eight office visits over roughly 20 weeks, with one visit requiring a compensated two-night stay, and all study-related medical care provided at no cost.
With 58.5 million U.S. adults living with arthritis and that number projected to hit 78 million by 2040, the demand for clinical trial participants has never been higher. There are currently 17 active arthritis clinical trials and 46 rheumatoid arthritis trials specifically seeking volunteers nationwide, according to PolicyLab tracking data. This article covers what these studies actually pay, which trials are recruiting right now, how to find legitimate opportunities near you, what the enrollment process looks like, and what to watch out for before you sign up.
Table of Contents
- How Much Do Arthritis Clinical Trials Pay and What Determines the Amount?
- Which Arthritis Studies Are Currently Recruiting Participants in 2026?
- What Types of Arthritis Qualify for Paid Research Studies?
- How to Find and Enroll in Legitimate Arthritis Clinical Trials
- What Are the Risks and Limitations of Participating in Arthritis Trials?
- How Clinical Trial Payments Are Changing in 2026
- New Arthritis Treatments on the Horizon and What They Mean for Future Trials
- Conclusion
- Frequently Asked Questions
How Much Do Arthritis Clinical Trials Pay and What Determines the Amount?
Compensation for arthritis clinical trials varies widely based on the phase of the study, the number of visits required, and how invasive the procedures are. Phase 2 through Phase 4 trials — the most common type recruiting arthritis patients — typically pay $50 to $100 per visit. A study requiring 8 visits would put you in the $400 to $800 range before travel reimbursement. Phase 1 trials, which test new treatments in smaller groups for the first time, often pay substantially more because they carry greater uncertainty and require more intensive monitoring. Some trials distribute compensation through electronic payment cards, with amounts ranging from $325 to $475 per study. The payment is not meant to be income. Regulatory guidance from the NIH requires that compensation amounts and timing be described in the informed consent materials you sign before enrolling.
The money covers your time and inconvenience — sitting in waiting rooms, filling out questionnaires, getting bloodwork done. On top of that, most trials separately reimburse travel costs to and from the clinic, and all study-related medical care, lab work, and medications are provided at no cost. For someone managing arthritis with expensive biologics or specialty drugs, the free medical care alone can represent significant value beyond the cash compensation. It is worth comparing this to other paid research. Focus groups and market research studies for pharmaceutical companies might pay $150 to $300 for a single two-hour session, but they do not include any medical benefit. Clinical trials require a longer commitment but offer both compensation and access to treatments that may not yet be available to the public. The tradeoff is real time investment — a 20-week study is not a casual commitment.
Which Arthritis Studies Are Currently Recruiting Participants in 2026?
The landscape of actively recruiting arthritis trials in 2026 is unusually active, driven partly by a wave of new treatment approaches moving through the pipeline. At UCSF, researchers are running a randomized, double-blind, placebo-controlled study testing platelet-rich plasma injections for osteoarthritis. Also at UCSF, a separate trial is examining the long-term safety of gene-modified regulatory T cell therapy for rheumatoid arthritis — a fundamentally different approach that aims to retrain the immune system rather than suppress it. UC San Diego is testing an AAV gene therapy called GNSC-001, delivered as a single injection for painful knee osteoarthritis. Other major research centers have their own trials underway. UC Davis is evaluating a treatment called CNTX-6970 for knee osteoarthritis pain.
Northwestern University in Chicago is running a knee OA pain trial lasting approximately 20 weeks. In Atlanta, a multicenter trial is comparing genicular artery embolization — a minimally invasive procedure that reduces blood flow to inflamed knee tissue — against standard steroid injections over a 24-month period. A Dallas-based study is testing multiple doses of PCRX-201 injection for patients ages 45 to 80 with knee osteoarthritis. However, eligibility requirements can be strict and may disqualify you even if your diagnosis matches. For rheumatoid arthritis, one study comparing upadacitinib versus adalimumab is specifically recruiting patients who had an inadequate response to TNF-inhibitor therapy and are on stable methotrexate — meaning you need a documented treatment history, not just a diagnosis. A trial for zasocitinib in psoriatic arthritis requires that participants have not previously used biologic DMARDs. If you have already cycled through multiple biologics, some trials will not accept you. Always read the full eligibility criteria before investing time in the screening process.
What Types of Arthritis Qualify for Paid Research Studies?
Osteoarthritis is by far the most common form of arthritis in the U.S., affecting an estimated 33.2 million adults — roughly 49.6 percent of all arthritis cases. Because it is so prevalent, osteoarthritis studies tend to have the largest recruitment needs, particularly for knee OA. Rheumatoid arthritis, the second most common subtype at 15.8 percent of cases (about 10.6 million people), drives a significant share of pharmaceutical research because it involves the immune system and responds to the biologic drugs that represent the industry’s biggest revenue generators. Psoriatic arthritis, though less common at roughly 1.4 percent of cases (about 1 million people), has become a major focus of clinical research following a string of new drug approvals. The top states for trial availability right now are Florida, Texas, California, Arizona, and Pennsylvania. This concentration reflects where major research institutions and clinical trial sites are located, but it also means participants in rural areas or smaller states may need to travel. Most trials cover travel costs, but a study requiring biweekly visits over five months is far more practical if the clinic is a 30-minute drive rather than a flight.
If you live outside these states, ClinicalTrials.gov allows you to search by ZIP code and set a radius, which can surface smaller local sites you might not have heard of. The demographic profile of arthritis also matters for trial recruitment. Nearly 54 percent of U.S. adults aged 75 and older have arthritis, compared to just 3.6 percent of those ages 18 to 34. Women are diagnosed at higher rates than men — 26 percent versus 20 percent. Clinical trials actively need diverse participant pools to ensure treatments work across different populations, so researchers are often specifically recruiting younger patients, men, and people from underrepresented racial and ethnic groups. If you fall into one of these categories, you may find it easier to qualify.
How to Find and Enroll in Legitimate Arthritis Clinical Trials
The most reliable starting point is ClinicalTrials.gov, the federal database where all registered studies in the United States must be listed. You can search by condition — enter “arthritis,” “rheumatoid arthritis,” or “osteoarthritis” — and filter by location, recruitment status, and study phase. Each listing includes the eligibility criteria, study description, compensation details (when provided), and contact information for the research site. The Arthritis Foundation also maintains a clinical trial participation portal that curates opportunities specifically for arthritis patients, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the NIH highlights featured trials on its website. Beyond these databases, individual research institutions post their own trials. UCSF, UC San Diego, UC Davis, and Northwestern all maintain searchable clinical trial directories on their websites.
Private research networks like Clinical Research of West Florida post studies directly and allow you to pre-screen online. The tradeoff between academic medical centers and private research sites is worth considering: academic centers tend to run more innovative, earlier-phase studies with potentially groundbreaking treatments, while private sites often run later-phase confirmatory trials that may involve less experimental risk but also less novelty. Both pay participants, but the visit schedules and time commitments can differ significantly. One practical comparison: a Phase 1 gene therapy trial at a university hospital might require several days of intensive monitoring and close follow-up for a year, with higher compensation reflecting that burden. A Phase 3 trial at a private clinic testing a drug that already has safety data from earlier phases might require monthly check-ins for six months with more modest per-visit payments. Neither is inherently better — it depends on your comfort level with experimental treatments and how much time you can commit.
What Are the Risks and Limitations of Participating in Arthritis Trials?
The most important limitation to understand is the placebo-controlled design used in many arthritis trials. In the UCSF platelet-rich plasma study, for instance, participants are randomized in a double-blind fashion, meaning neither you nor your doctor knows whether you are receiving the actual treatment or a placebo injection. If you are in the placebo group, you will go through all the visits, time commitment, and procedures without receiving the experimental treatment. You will still be compensated and receive standard medical monitoring, but you should not enroll expecting guaranteed access to a new therapy. Side effects are another consideration that varies enormously by study. A trial testing a topical cream for knee pain carries different risks than one involving gene-modified T cells or AAV gene therapy injections.
The informed consent document will outline known risks, but by definition, clinical trials are testing things that are not fully proven. The recent FDA approvals offer some reassurance about the general direction of research — bimekizumab-bkzx was approved in 2025 for psoriatic arthritis and related conditions, and Sotyktu became the first oral TYK2 inhibitor approved for psoriatic arthritis in March 2026 — but the drugs currently in trials have not yet cleared that bar. There is also the time commitment to be realistic about. A study spanning 20 weeks with eight visits is nearly five months of your life. The Atlanta genicular artery embolization trial runs for 24 months. If your arthritis symptoms improve or worsen during the study, or if you experience side effects, withdrawing early may mean forfeiting remaining compensation. Read the consent form carefully to understand the withdrawal policy before you commit.
How Clinical Trial Payments Are Changing in 2026
The payment infrastructure for clinical trials is catching up with the rest of the financial world. The industry is shifting toward digital, near-real-time payment methods including prepaid cards, instant bank transfers, and digital wallets. This matters practically because older payment systems — paper checks mailed weeks after a visit — created friction that discouraged some participants from completing studies.
If you are evaluating two similar trials, the one offering electronic payment cards with prompt disbursement may be worth prioritizing simply for convenience. Compensation in clinical trials falls into four distinct categories: participant compensation for your time and inconvenience, reimbursement for direct expenses like travel and meals and childcare, site payments to the research facility, and vendor payments. As a participant, you should ask during the screening process exactly which categories apply to you and when payments are disbursed — some trials pay per visit, while others pay a lump sum at the end, and others use milestone-based schedules.
New Arthritis Treatments on the Horizon and What They Mean for Future Trials
The recent wave of FDA approvals suggests that arthritis research is entering a period of rapid diversification. The SetPoint System, a first-of-its-kind neuroimmune modulation device approved for moderate-to-severe RA, represents an entirely new treatment category — using electrical stimulation of the vagus nerve rather than drugs to modulate the immune response. Gene therapies like the GNSC-001 trial at UC San Diego aim for one-time injections that could provide lasting relief.
Pediatric arthritis treatment also expanded in 2025, with certolizumab pegol, sarilumab, and upadacitinib all receiving new approvals for polyarticular juvenile idiopathic arthritis. For people considering clinical trial participation, this pipeline means more opportunities in the coming years, likely with increasingly competitive compensation as sponsors compete for qualified participants. The 67.1 million Americans currently diagnosed with arthritis represent a massive potential participant pool, but the specific eligibility requirements for each trial narrow that pool considerably. Getting into trial databases now, establishing a relationship with a research site, and keeping your medical records current positions you to move quickly when a well-matched study opens up.
Conclusion
Arthritis clinical trials paying $200 to $1,500 or more are actively recruiting across the country, with the highest concentration of opportunities in Florida, Texas, California, Arizona, and Pennsylvania. Compensation varies by study phase and duration, but most trials also cover travel costs and provide all study-related medical care at no charge. Whether you are living with osteoarthritis, rheumatoid arthritis, or psoriatic arthritis, there are currently dozens of active studies testing treatments ranging from conventional drug comparisons to gene therapies and neuroimmune devices.
The practical next step is straightforward: search ClinicalTrials.gov by your specific arthritis type and location, check the Arthritis Foundation’s clinical trial portal, and contact research sites directly to ask about compensation details and eligibility requirements. Read the informed consent documents carefully, understand the time commitment and placebo possibility, and make sure the study schedule works with your life before you sign up. Paid clinical trials are a legitimate way to access new treatments and earn compensation for your time, but they are a commitment — treat the decision with the same seriousness you would any medical choice.
Frequently Asked Questions
Do I need health insurance to participate in an arthritis clinical trial?
No. Clinical trials provide all study-related medical care, lab work, and medications at no cost to participants. Your insurance status does not typically affect eligibility, though some trials may require that you have a confirmed diagnosis from a physician.
Will I definitely receive the new treatment being tested?
Not necessarily. Many arthritis trials use a placebo-controlled design where some participants receive an inactive treatment. In double-blind studies, neither you nor the research team knows which group you are in until the study concludes.
How long do most arthritis clinical trials last?
It varies widely. Some studies run 8 to 12 weeks, while others last 20 weeks to 24 months. The listing on ClinicalTrials.gov will specify the expected duration and number of visits before you apply.
Can I continue taking my current arthritis medications while in a trial?
It depends on the study. Some trials require a washout period where you stop certain medications before enrolling. Others, like the upadacitinib study, specifically recruit patients who are on stable methotrexate. The eligibility criteria will spell this out, and you should discuss it with both the research team and your own doctor.
When and how do I get paid?
Payment timing varies by study. Some trials pay per visit, others at milestones, and some at study completion. The industry is shifting toward electronic payment cards and digital transfers for faster disbursement. The informed consent document must describe compensation amounts and schedules before you enroll.
Can I withdraw from a trial if I want to stop participating?
Yes. Participation in any clinical trial is voluntary, and you can withdraw at any time without penalty to your regular medical care. However, leaving early may affect your remaining compensation, so review the withdrawal terms in your consent form.
